Dr Miyamoto speaks with ecancer at the 2018 ASCO Genitourinary Cancers Symposium about genomic profiling of muscle invasive bladder cancer to predict response to bladder-sparing trimodality therapy.
He goes on to highlight that transcriptional profiling of muscle invasive bladder cancer revealed gene signatures correlated with response to chemoradiation, suggesting the potential of genomics to guide use of trimodality therapy.
